Considerable scale-up is needed to achieve the 2025 goals for HIV pre-exposure prophylaxis (PrEP), according to study findings.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the ...

Cidara Therapeutics (CDTX) announced it has reached full planned enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across clinical ...

Indiana laws criminalizing human immunodeficiency virus (HIV) transmission are “outdated” and largely unnecessary, asserts a ...

Even though HIV is just one of a vast number of viruses that infect people, there can still be a stigma surrounding it. To break through that, experts answer some questions about the virus, such as ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Approved by the FDA 12 years ago, pre-exposure prophylaxis (PrEP) has significantly reduced the risk of HIV transmission and ...

Tengrinews.kz - A revolutionary HIV drug has been created: clinical trials have shown that its twice-yearly injections are 96 ...

In the context of World AIDS Day (December 1), the Pan American Health Organization (PAHO) has launched the “Better with PrEP ...

With Sunday marking the 37th annual World AIDS Day, the Michigan Department of Health and Human Services (DHHS) released its ...